Related by context. All words. (Click for frequent words.) 66 fosbretabulin 63 Phase Ib clinical 62 receptor tyrosine kinase inhibitor 61 VNP#M 61 humanized monoclonal 61 histone deacetylase HDAC inhibitor 61 Kinase Inhibitor 61 gemcitabine Gemzar ® 60 phase IIa clinical 60 depsipeptide 60 cetuximab Erbitux ® 60 novel anticancer 60 GW# [003] 60 pertuzumab 60 novel histone deacetylase 60 Cloretazine R 60 multikinase inhibitor 60 Factor VIIa 60 histone deacetylase inhibitor 60 Phase Ib II 60 preclinical efficacy 59 pharmacokinetic PK study 59 mertansine 59 aurora kinase 59 ARC# [001] 59 omacetaxine mepesuccinate 59 PDE4 inhibitor 59 Phase IIb clinical trials 59 liposomal formulation 59 Enzastaurin 58 Cloretazine 58 Phase Ib Clinical Trial 58 PEG IFN 58 PEGylated interferon beta 1a 58 bortezomib Velcade 58 volociximab 58 Phase Ib study 58 vidofludimus 58 irreversible inhibitor 58 Phase III randomized controlled 58 Pharmacokinetics PK 58 HDAC Inhibitor 58 antisense inhibitor 58 SYN# 58 PKC# 58 Phase 1b clinical trials 58 KSP inhibitors 58 Cloretazine ® 58 Tyrosine Kinase Inhibitor 58 ENMD # 58 selective antagonist 58 RhuDex ® 58 Squalamine 58 histamine dihydrochloride 58 TLK# 58 Phase #b/#a trial 58 AQ4N 57 phase IIa 57 PI3K/mTOR 57 CLL SLL 57 Onconase 57 sorafenib Nexavar 57 acadesine 57 dose escalation clinical 57 Aplidin R 57 beta 1a 57 Phase #b/#a 57 novel immunotherapeutic 57 Anti angiogenic 57 Phase #b/#a clinical 57 Janus Kinase 57 pharmacodynamic PD 57 compound AEZS 57 targeted antifolate 57 ZYBRESTAT TM 57 humanised monoclonal antibody 57 multiple myeloma MM 57 Annamycin 57 obatoclax 57 small molecule tyrosine 57 Immunotherapeutic 57 KRN# 57 Aflibercept 57 Phase 2a trial 57 JAK1 57 intratumoral injection 57 inhibitor RG# 57 pan HDAC inhibitor 57 bevacizumab Avastin ® 57 IL# PE#QQR 56 PI3K inhibitor 56 relapsing multiple sclerosis 56 prostate cancer mCRPC 56 generation purine nucleoside 56 TLR8 agonist 56 Neulasta ® 56 JAK2 inhibitors 56 DNA intercalator 56 erlotinib Tarceva ® 56 clevidipine 56 AKT inhibitor 56 GLP toxicology studies 56 Panzem ® 56 antiangiogenic agent 56 TLR9 agonist 56 metastatic malignant 56 Phase IIA 56 NPC 1C 56 Panzem R NCD 56 gemtuzumab ozogamicin 56 CEQ# 56 Blinatumomab 56 Phase 1a clinical 56 reversible inhibitor 56 dasatinib Sprycel 56 BrachySil TM 56 lymphoid malignancies 56 erythropoietic 56 immunomodulatory therapy 56 BAL# [002] 56 p# inhibitor 56 satraplatin Phase 56 assessing T DM1 56 Kahalalide F 56 somatostatin analogue 56 TRO# 56 Antiviral Activity 56 small molecule activator 56 demonstrated antitumor activity 56 stated Michelle Berrey 56 Anti VEGF 56 selective kinase inhibitor 56 YONDELIS R 55 AACR NCI EORTC 55 non nucleoside 55 preclinically 55 potently inhibit 55 levodopa induced dyskinesia 55 cetuximab Erbitux R 55 cytostatic 55 radiotherapeutic 55 peptidomimetic 55 radiolabeled monoclonal antibody 55 thalidomide Thalomid 55 HuMax CD4 55 Presents Preclinical Data 55 sunitinib Sutent 55 antimitotic 55 Neupogen ® 55 novel peptide 55 selective adenosine 55 immunotherapeutic vaccine 55 Potent Inhibitor 55 Triapine R 55 Hsp# Inhibitor 55 anti angiogenic agent 55 relapsed refractory 55 Novel Small Molecule 55 Reports Preclinical Data 55 pharmacokinetic PK 55 Trofex 55 Phase Ib IIa clinical 55 huN# DM1 55 Cytochrome P# 55 monoclonal antibody mAb 55 Geron telomerase inhibitor 55 chimeric monoclonal antibody 55 peptide conjugated 55 transplantation ASCT 55 CDK inhibitor 55 Phase III psoriasis 55 GRNVAC1 55 Gleevec resistant 55 YONDELIS 55 Kinase inhibitor 55 dasatinib Sprycel ® 55 EGFR HER2 55 Abstract Number 55 inhibitor ARRY 54 paclitaxel Taxol 54 NEUGENE antisense 54 p# MAP kinase inhibitor 54 Bevasiranib 54 viral kinetics 54 Interferon Alfa 54 imatinib Gleevec ® 54 transthyretin TTR mediated amyloidosis 54 PSN# [002] 54 radiolabeled 54 alpha 2a 54 Phase 1b trial 54 Apoptone 54 bendamustine 54 bevacizumab Avastin R 54 Radezolid 54 Ceflatonin 54 Cytoxan ® 54 teriflunomide 54 Vidaza azacitidine 54 Interferon alpha 54 BEZ# 54 EORTC 54 antitumoral 54 malignant ascites 54 proteasome inhibitor 54 stem cell mobilizer 54 angiogenesis inhibitor 54 EOquin TM 54 estramustine 54 mGluR2 NAM 54 lexidronam injection 54 verteporfin 54 Angiotensin Converting Enzyme 54 ON #.Na 54 Bosutinib 54 Generx ™ 54 potent cytotoxic 54 polycythemia vera essential thrombocythemia 54 NEUGENE 54 Liposomal 54 Immunomodulatory 54 vitro cytotoxicity 54 HQK 54 Pertuzumab 54 xenograft model 54 JAK2 inhibitor 54 MEK inhibitor 54 PF # [002] 54 mediated inhibition 54 HER2 antibody 54 rALLy clinical trial 54 cell lymphoma CTCL 54 subcutaneous SC 54 fludarabine cyclophosphamide 54 trodusquemine 54 Myelodysplastic Syndrome MDS 54 radioimmunotherapy RIT 54 galiximab 54 tyrosine kinase inhibitor 54 mTOR inhibitor 54 HGS# 54 M Vax 54 Forodesine 54 antibody blinatumomab MT#/MEDI-# 54 Denufosol 54 axitinib 54 antiproliferative effects 54 orally dosed 54 Revlimid lenalidomide 54 nucleoside analog 54 Bruton tyrosine kinase Btk 54 denileukin diftitox 54 combinability 54 Traficet EN 54 mapatumumab 54 AVI NEUGENE 54 maturation inhibitor 54 ara C 54 Epothilone 54 ZACTIMA 54 CRLX# 54 Pathway Inhibitor 54 patientswith 54 lorvotuzumab mertansine 54 chemotherapeutic regimen 54 Hedgehog pathway inhibitor 54 riociguat 54 immunoconjugate 54 Zenvia Phase III 54 ganaxolone 54 Omacetaxine 54 lenalidomide Revlimid 53 vinca alkaloid 53 mTOR inhibitors 53 pharmacodynamic properties 53 antiproliferative activity 53 Antiangiogenic 53 HuLuc# 53 Hedgehog antagonist 53 tyrosine kinase inhibitors TKIs 53 preclinical pharmacokinetic 53 essential thrombocythemia ET 53 RezularTM 53 targeted radiotherapeutic 53 IFN Beta 53 bleomycin 53 UPLYSO 53 Dalbavancin 53 Fenretinide 53 MET VEGFR2 53 Quinamed 53 EZN 53 alemtuzumab Campath 53 ritonavir boosted 53 intravesical 53 intravesical instillation 53 Btk inhibitor 53 PPARgamma 53 dimeglumine 53 Aurora Kinase 53 immune modulation 53 BrachySil ™ 53 aurora kinase inhibitor 53 ARRY # 53 systemic RNAi therapeutic 53 selective modulator 53 administered intraperitoneally 53 evaluating tivozanib 53 Anticalin ® 53 liposome formulation 53 Alocrest 53 RhuDex 53 fistulizing Crohn disease 53 indibulin 53 Carfilzomib 53 murine models 53 subcutaneously administered 53 CCR5 antagonist 53 ACOMPLIA R 53 NMDA antagonists 53 NS5A 53 adenoviral 53 P2Y 53 Morpholino 53 Zybrestat 53 eniluracil 53 phase IIb study 53 CCX# 53 Bortezomib 53 Amrubicin 53 topically administered 53 NOD SCID mice 53 JAK#/JAK# 53 Phase 2b Clinical Trial 53 anticancer compound 53 II Clinical Trial 53 Mycophenolate Mofetil 53 receptor blocker 53 MELAS 53 SR# [004] 53 GHRH 53 PSN# [001] 53 monoclonal anti 53 Alzhemed TM 53 syngeneic 53 azacytidine 53 Gastrointestinal Cancers Symposium 53 Azacitidine 53 mRCC 53 trastuzumab Herceptin 53 Topoisomerase 53 Eniluracil 53 rhITF 53 antibody MAb 53 Receptor Antagonists 53 selective inhibition 53 microtubule inhibitor 53 Investigational Oral 53 MORAb 53 Pharmacodynamic 53 oblimersen 53 therapeutically relevant 53 CanAg 53 HERCEPTIN 53 Intra arterial 53 nonclinical studies 52 serine protease inhibitor 52 recurrent glioblastoma multiforme 52 MGd 52 trabectedin 52 antisense inhibitors 52 Angiolix 52 neoadjuvant setting 52 somatostatin analog 52 OncoVex 52 Tyrosine Kinase Inhibitors 52 ATIR 52 Tesetaxel 52 BAL# [001] 52 multicentre randomized 52 ibritumomab tiuxetan 52 PEG SN# 52 tkRNAi 52 NK1 52 TG# [001] 52 CRMD# 52 isatoribine 52 SMT C# 52 haematologic malignancies 52 Capesaris 52 liposome injection 52 potent inhibitor 52 tumors GIST 52 Irinotecan 52 CCR1 52 CCR2 52 NanoEmulsion 52 OHR/AVR# 52 radiolabelled 52 DMAG 52 hydroxamic acid 52 PSMA ADC 52 CG# [003] 52 Glycosylation 52 RhuDex R 52 histone deacetylase 52 refractory prostate cancer 52 leukemia AML 52 Phase III TRIST 52 Alequel 52 epoetin alpha 52 HepaSphere 52 microtubule targeting 52 alfa 2a 52 R roscovitine 52 hypomethylating agent 52 IIa trials 52 OvaRex MAb 52 intradermal injections 52 Androxal TM 52 Anti Tumor 52 TASKi3 52 PTK# 52 anti angiogenic agents 52 Polymerase Inhibitor 52 Degarelix 52 entitled Synergistic 52 cMET 52 Vascular Wrap TM 52 murine monoclonal antibody 52 Chemophase 52 Cimzia ® certolizumab pegol 52 IIa trial 52 Glypromate 52 cyclophilin inhibitors 52 BCG refractory 52 Phase III Clinical Trial 52 Phase IIb trials 52 administered subcutaneously 52 Removab 52 Ocrelizumab 52 pain palliation 52 Kinase Inhibitors 52 etoposide 52 PEGPH# 52 vWF 52 HDL Mimetic Peptide 52 Melphalan 52 docetaxel Taxotere 52 platelet inhibitor 52 cathepsin K inhibitor 52 CINTREDEKIN BESUDOTOX 52 Guanilib 52 Phase 2a Clinical Trial 52 Sym# 52 HDL Selective Delipidation 52 Parathyroid Hormone 52 mitomycin 52 Temsirolimus 52 gastrointestinal stromal tumors GIST 52 rilonacept 52 NEUGENE R 52 JAK2 Inhibitor 52 murine model 52 pomalidomide 52 Fludarabine 52 Preclinical Data 52 annexin 52 ASSERT trial 52 NSCLC tumors 52 MDS AML 52 Cytotoxic 52 bevacizumab Avastin 52 Dacogen decitabine 52 Elitek 52 liposomal doxorubicin 52 Yondelis ® 52 Gleevec imatinib mesylate 52 Kamada AAT 52 PORxin TM 52 ECCMID 52 E1 INT TM 52 HuMax 52 Bruton tyrosine kinase 52 incyclinide 52 Multiple Ascending Dose 52 Phase III Psoriasis 52 Tarvacin 52 investigational therapies 52 vivo preclinical 52 MabCampath 52 CD3 monoclonal antibody 52 QLT# 52 Bendamustine 52 EndoTAG TM -1 52 refractory colorectal cancer 52 cyclin dependent kinase inhibitor 51 ALK inhibitor 51 mouse xenograft models 51 EGS# 51 demethylating agent 51 Campath alemtuzumab 51 colon carcinoma 51 monocytes macrophages 51 imatinib resistant 51 secretory phospholipase A2 sPLA2 51 imatinib therapy 51 NABTT 51 baminercept 51 IL 1ß 51 RAV# 51 Pemetrexed 51 OvaRex 51 phase IIIb 51 AMEVIVE 51 FVIIa 51 prospective multicenter study 51 Solorel TM 51 alefacept 51 refractory chronic lymphocytic 51 CLARITY study 51 chemoresistant 51 Sorafenib Nexavar 51 cutaneous T 51 ATL/TV# 51 valopicitabine NM# 51 Sutent sunitinib 51 Dasatinib 51 PEGylated interferon 51 Tumor Necrosis Factor 51 Ataluren 51 SAR# [004] 51 paclitaxel carboplatin 51 VEGF inhibitors 51 SABCS 51 Tigecycline 51 ESHO 51 TransMID 51 gastrointestinal stromal tumors GISTs 51 Noxafil 51 papillary renal cell carcinoma 51 thrombin receptor 51 interferon lozenges 51 unresectable inoperable 51 farletuzumab 51 glatiramer acetate GA 51 immunostimulatory 51 Erbitux cetuximab 51 Sapacitabine 51 BCR ABL inhibitor 51 Prodrug 51 PegIFN 51 anti CD3 51 ixabepilone 51 Convection Enhanced Delivery 51 tocilizumab 51 Doxil ® 51 gemcitabine Gemzar 51 Pimavanserin 51 INGN 51 haematological cancers 51 Archexin 51 Kinoid 51 inhaled AAT 51 novel prodrug 51 polycythemia vera PV 51 CINOD 51 eluting stent 51 thetreatment 51 vivo potency 51 tiuxetan 51 #nd EORTC NCI 51 LHRH agonists 51 rALLy trial 51 PARP Inhibitor 51 Chemokine 51 cilengitide 51 relapsed ALL 51 sunitinib malate 51 Pivotal Trial 51 etanercept Enbrel 51 busulfan 51 prostate cancer HRPC 51 ascending dose 51 Inhibits Growth 51 BMS# 51 hA# 51 ALN HTT 51 ICAAC IDSA 51 prostate cancer AIPC 51 Allovectin 7 51 lapatinib Tykerb 51 G CSFs 51 AACR #st Annual Meeting 51 cationic lipid 51 recurrent NSCLC 51 glycoprotein GP IIb IIIa 51 VAPRISOL 51 LHRH receptor positive 51 intravenous recombinant 51 TLR8 51 TORISEL TM 51 multicenter phase 51 Btk Inhibitor 51 novel mTOR inhibitor 51 Alkeran 51 adjuvant cisplatin 51 beta interferons 51 Cintredekin besudotox 51 IFN α 51 ISF# 51 JAK2 V#F 51 Trastuzumab 51 HER2 positive metastatic breast 51 histone deacetylase HDAC 51 antimetabolite 51 Enzyme Replacement Therapy 51 tumorigenicity 51 HCV polymerase inhibitor 51 pediatric acute lymphoblastic 51 heavily pretreated patients 51 phosphatidylserine PS targeting 51 epigenetic therapies 50 refractory acute myeloid 50 PPAR gamma agonist 50 Antiviral Therapy 50 PDE# inhibitors 50 visilizumab 50 multicenter randomized controlled 50 Epratuzumab 50 Anti Phospholipid Therapy 50 Phase IIIb study 50 talabostat 50 mda 7 50 CALGB 50 Erlotinib 50 Vitro Activity 50 IGF 1R inhibitor 50 paclitaxel poliglumex 50 midstage clinical 50 Neoadjuvant 50 neoadjuvant treatment 50 AVAX 50 imatinib Gleevec 50 concurrent chemoradiation 50 PhG alpha 1 50 zalutumumab 50 reteplase 50 Zenvia ™ 50 SinuNase ™ 50 5 HT4 receptor 50 Proteasome 50 Antitumor 50 MEND CABG 50 SMIP 50 cleavable linker 50 oral JAK1 50 ® C1 esterase 50 IMC #B 50 Dacogen injection 50 TKI therapy 50 TASQ 50 telomerase activator 50 PSMA antibody 50 Protease Inhibitor 50 HCV polymerase 50 prognostic biomarker 50 SGLT 50 metastatic castration resistant 50 Systemic Delivery 50 Intravesical 50 Deforolimus 50 ASCT 50 Fx #A 50 Triapine 50 cisplatin gemcitabine 50 null responder 50 ribavirin RBV 50 multicentric 50 colorectal cancer liver metastases 50 G Protein Coupled 50 Trophos 50 alpha antagonist 50 gefitinib Iressa 50 tipifarnib 50 adalimumab Humira 50 Novel Oral 50 Diffuse Large B 50 intranasal delivery 50 solithromycin 50 Epirubicin 50 Systemic Sclerosis 50 renin inhibitor 50 Teriflunomide 50 oral tyrosine kinase 50 STEDESA 50 tarenflurbil 50 CALGB # [002] 50 Patients Treated With 50 siRNAs targeting 50 ASH Annual Meeting 50 Initiates Phase 2b 50 Novel Inhibitor 50 Late Breaker 50 decitabine 50 liposomal amphotericin B 50 epothilones 50 potent suppressor 50 favorable pharmacokinetic profile 50 receptor antagonism 50 flavopiridol 50 biliary tract cancer 50 SCCHN 50 Fulvestrant 50 multicenter prospective 50 gemcitabine carboplatin 50 sodium glucose cotransporter 50 HCV Genotype 50 immunomodulatory agents 50 briakinumab 50 Multiple Myeloma MM 50 HepG2 cells 50 JVRS 50 Fluconazole 50 DEB# 50 Plenaxis TM 50 pharmacodynamic markers 50 XL# [003] 50 Glatiramer acetate 50 Pharmacological 50 Interferon alfa 50 humanized monoclonal antibodies 50 Prolongs Survival 50 A3 adenosine receptor 50 Phase 2b Trial 50 Interferon Beta 50 Manja Bouman CEO 50 BAY #-# 50 Inosine 50 biologic therapy 50 Talabostat 50 Pegylated Liposomal Doxorubicin 50 KSP inhibitor 50 pT2 50 sedative pentobarbital sodium 50 Mutation Analysis 50 Inhaled AAT 50 Thiovir 50 Safinamide 50 pancreatic islet cell 50 chemokine receptor 50 Bendavia 50 Specifid 50 RNA antagonist 50 vorinostat 50 myeloid metaplasia 50 hypereosinophilic syndrome 50 metastatic renal cell carcinoma 50 NeuVax 50 CHOP chemotherapy 50 Cardiotoxicity 50 Protein Kinase C 50 bispecific antibody 50 rxRNA 50 ALN TTR 50 cidofovir 50 thyroid hormone receptor 50 BCIRG 50 DermaVir Patch 50 Inhalation Solution 50 PEG Interferon 50 tumor specific antigen 50 dexpramipexole 50 GRNCM1 50 BiTE 50 DCVax ® Brain 50 anti fibrotic 50 cellular cytotoxicity 50 cinacalcet 50 nucleotide analog 50 vinblastine 50 doxorubicin docetaxel 50 Successfully Completes Phase 50 Elvitegravir 50 Refractory Angina 50 urothelial bladder cancer 50 Beta catenin pathway 49 dexamethasone Decadron 49 KN# [001] 49 Synta Announces 49 Factor 5A 49 proteasome inhibitors 49 samalizumab 49 Mipomersen 49 Camptothecin 49 antisense oligonucleotide 49 Lp PLA 2 49 Modrenal 49 Monoclonal Antibody 49 trastuzumab Herceptin ® 49 refractory ovarian cancer 49 uricase 49 Aptamer 49 CCL2 49 Kineret R 49 Oritavancin 49 Entry Inhibitor 49 Receptor Antagonist 49 Bosentan 49 cediranib 49 Vidofludimus 49 temozolomide TMZ 49 vismodegib 49 anti VEGF 49 dose cohort 49 chemosensitivity 49 temozolomide Temodar 49 Certolizumab pegol 49 palifermin 49 HepDirect prodrug 49 Interferon Gamma 49 siRNA duplexes 49 2DG 49 non nucleoside HCV 49 melphalan prednisone 49 humanized antibody 49 plerixafor 49 biotherapy 49 mg kg BID 49 anticancer therapeutics 49 pegylated liposomal doxorubicin 49 ANTEGREN 49 Antiviral 49 nd Annual Meeting 49 protein kinase inhibitors 49 bacillus Calmette Guerin 49 Temozolomide 49 gemcitabine cisplatin 49 rBChE 49 SIR Spheres 49 soluble receptor 49 TRAIL receptors 49 ghrelin antagonists 49 cetuximab Erbitux 49 HLA A2 49 stage IIIB 49 IFN Beta CTP 49 Epidermal Growth Factor Receptor 49 genomic biomarker 49 abacavir Ziagen 49 refractory CLL 49 Roflumilast 49 Metastatic Melanoma 49 ChronVac C R 49 MAGE A3 49 ocrelizumab 49 colorectal carcinoma 49 lorcaserin Phase 49 Arranon 49 xenograft 49 Clolar ® 49 Mitomycin 49 MabThera rituximab 49 investigational immunotherapy 49 agonist compounds 49 nicotinic acetylcholine receptor 49 Cimzia TM 49 DCVax 49 1α 49 Intravitreal 49 Hodgkin lymphoma NHL 49 CRp 49 SEPET TM 49 Nuvion 49 GAMMAGARD 49 FRDA 49 kidney urologic 49 relapsed CLL 49 urothelial 49 skip exon 49 Olaparib 49 monoclonal antibody conjugated 49 AmpliMed 49 EGFR TKIs 49 5 Fluorouracil 49 PNT# 49 Therapeutic Vaccine 49 AZILECT R 49 #th Interscience Conference 49 castrate resistant 49 HoFH 49 Elafin 49 oral picoplatin 49 fusion inhibitor 49 Liprostin 49 renin inhibitors 49 pamidronate 49 taxane refractory 49 Solid Tumors 49 5 fluorouracil leucovorin 49 anti CD3 antibody 49 annexin V 49 Kineret ® 49 Trandolapril 49 MAb 49 recurrent glioma 49 metastatic gastric 49 ß blockers 49 Vascugel ® 49 Lenalidomide 49 Selective Internal 49 randomized multicenter Phase III 49 intratumoral 49 eculizumab 49 PI3 kinase inhibitor 49 Eculizumab 49 prospective multicenter 49 Janus kinase 49 AFFiRiS 49 metastatic pancreatic 49 previously untreated follicular 49 atazanavir Reyataz 49 paclitaxel Taxol R 49 nonmetastatic 49 Phase IIb IIIa 49 Shc 49 #F FDG 49 Acute Ischemic Stroke 49 olaparib 49 MVA BN 49 Monoclonal 49 myeloproliferative 49 Velcade bortezomib 49 CVac 49 metastatic malignant melanoma 49 LT NS# 49 erlotinib Tarceva 49 myocardial revascularization 49 investigational HCV polymerase 49 dose melphalan 49 Targeted Anticancer Therapies 49 AEG# 49 REVIVE Diabetes 49 Symadex 49 RRM1 49 International Myeloma Workshop 49 drug zotarolimus 49 ZYBRESTAT fosbretabulin 49 adriamycin 49 Cutaneous T 49 induced cytotoxicity 49 recurrent metastatic 49 lymphomas leukemias 49 BMS # 49 Cyclosporin 49 pegfilgrastim 49 CHAMPION PCI 49 randomized multicenter trial 49 CAMPATH 49 idiopathic thrombocytopenic purpura 49 nab paclitaxel 49 Immune Therapy 49 heparanase 49 ESBA# 49 ZFP Therapeutic TM 49 ribavirin Copegus ® 49 ISTODAX ® 49 Analogs 49 rhMBL 48 Sanvar R 48 TEMODAL 48 Natalizumab 48 heavily pretreated 48 Resten MP 48 TheraGuide 48 DUROS 48 cytochrome P 48 Pharmacologic 48 EGFR TKI 48 Amplimexon 48 GRASPA ® 48 transgenic mouse models 48 Clevudine 48 prolyl hydroxylase inhibitors 48 HBeAg + 48 metastatic colorectal 48 B2A 48 Davanat 48 Virologic 48 ghrelin agonist 48 intralesional 48 QT Prolongation 48 Assay Kits 48 Hormone Refractory Prostate Cancer 48 LUMINATE 48 Macrophage 48 COPERNICUS 48 myeloproliferative disorders 48 Ceplene histamine dihydrochloride